215 related articles for article (PubMed ID: 20197733)
1. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Giaccone G; Rajan A; Ruijter R; Smit E; van Groeningen C; Hogendoorn PC
J Thorac Oncol; 2009 Oct; 4(10):1270-3. PubMed ID: 20197733
[TBL] [Abstract][Full Text] [Related]
2. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
3. Expression and mutational status of c-kit in thymic epithelial tumors.
Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
[TBL] [Abstract][Full Text] [Related]
4. When a thymic carcinoma "becomes" a GIST.
Rossi V; Donini M; Sergio P; Passalacqua R; Rossi G; Buti S
Lung Cancer; 2013 Apr; 80(1):106-8. PubMed ID: 23375402
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
7. A new KIT gene mutation in thymic cancer and a promising response to imatinib.
Lim SH; Lee JY; Sun JM; Kim KM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2013 Oct; 8(10):e91-2. PubMed ID: 24457249
[No Abstract] [Full Text] [Related]
8. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
9. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.
Buti S; Donini M; Sergio P; Garagnani L; Schirosi L; Passalacqua R; Rossi G
J Clin Oncol; 2011 Nov; 29(33):e803-5. PubMed ID: 21969494
[No Abstract] [Full Text] [Related]
10. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Dy GK; Miller AA; Mandrekar SJ; Aubry MC; Langdon RM; Morton RF; Schild SE; Jett JR; Adjei AA
Ann Oncol; 2005 Nov; 16(11):1811-6. PubMed ID: 16087693
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate in thymic epithelial malignancies.
Palmieri G; Marino M; Buonerba C; Federico P; Conti S; Milella M; Petillo L; Evoli A; Lalle M; Ceribelli A; Merola G; Matano E; Sioletic S; De Placido S; Di Lorenzo G; Damiano V
Cancer Chemother Pharmacol; 2012 Feb; 69(2):309-15. PubMed ID: 21710245
[TBL] [Abstract][Full Text] [Related]
15. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
16. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Ströbel P; Hartmann M; Jakob A; Mikesch K; Brink I; Dirnhofer S; Marx A
N Engl J Med; 2004 Jun; 350(25):2625-6. PubMed ID: 15201427
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
Horak P; Wöhrer A; Hassler M; Hainfellner J; Preusser M; Marosi C
J Neurooncol; 2012 Sep; 109(2):323-30. PubMed ID: 22610940
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
[TBL] [Abstract][Full Text] [Related]
19. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
20. Imatinib treatment for gastrointestinal stromal tumour (GIST).
Lopes LF; Bacchi CE
J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]